435 related articles for article (PubMed ID: 20957395)
1. Advanced glycation endproducts: from precursors to RAGE: round and round we go.
Ramasamy R; Yan SF; Schmidt AM
Amino Acids; 2012 Apr; 42(4):1151-61. PubMed ID: 20957395
[TBL] [Abstract][Full Text] [Related]
2. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes.
Ramasamy R; Yan SF; Schmidt AM
Vascul Pharmacol; 2012; 57(5-6):160-7. PubMed ID: 22750165
[TBL] [Abstract][Full Text] [Related]
3. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes.
Stern DM; Yan SD; Yan SF; Schmidt AM
Ageing Res Rev; 2002 Feb; 1(1):1-15. PubMed ID: 12039445
[TBL] [Abstract][Full Text] [Related]
4. The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs.
Xue J; Ray R; Singer D; Böhme D; Burz DS; Rai V; Hoffmann R; Shekhtman A
Biochemistry; 2014 May; 53(20):3327-35. PubMed ID: 24824951
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end products (AGEs) activate mast cells.
Sick E; Brehin S; André P; Coupin G; Landry Y; Takeda K; Gies JP
Br J Pharmacol; 2010 Sep; 161(2):442-55. PubMed ID: 20735427
[TBL] [Abstract][Full Text] [Related]
6. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease.
Schmidt AM; Stern DM
Front Biosci; 2001 Oct; 6():D1151-60. PubMed ID: 11578972
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T
Curr Drug Discov Technol; 2006 Mar; 3(1):83-8. PubMed ID: 16712466
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
[TBL] [Abstract][Full Text] [Related]
9. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy.
Wendt T; Tanji N; Guo J; Hudson BI; Bierhaus A; Ramasamy R; Arnold B; Nawroth PP; Yan SF; D'Agati V; Schmidt AM
J Am Soc Nephrol; 2003 May; 14(5):1383-95. PubMed ID: 12707408
[TBL] [Abstract][Full Text] [Related]
10. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings.
Stern D; Yan SD; Yan SF; Schmidt AM
Adv Drug Deliv Rev; 2002 Dec; 54(12):1615-25. PubMed ID: 12453678
[TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics.
Valencia JV; Weldon SC; Quinn D; Kiers GH; DeGroot J; TeKoppele JM; Hughes TE
Anal Biochem; 2004 Jan; 324(1):68-78. PubMed ID: 14654047
[TBL] [Abstract][Full Text] [Related]
12. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
Schmidt AM; Yan SD; Wautier JL; Stern D
Circ Res; 1999 Mar; 84(5):489-97. PubMed ID: 10082470
[TBL] [Abstract][Full Text] [Related]
13. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.
Yan SF; Ramasamy R; Schmidt AM
J Mol Med (Berl); 2009 Mar; 87(3):235-47. PubMed ID: 19189073
[TBL] [Abstract][Full Text] [Related]
14. Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes.
Brodeur MR; Bouvet C; Bouchard S; Moreau S; Leblond J; Deblois D; Moreau P
PLoS One; 2014; 9(1):e85922. PubMed ID: 24465790
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.
Ishibashi Y; Matsui T; Maeda S; Higashimoto Y; Yamagishi S
Cardiovasc Diabetol; 2013 Aug; 12():125. PubMed ID: 23984879
[TBL] [Abstract][Full Text] [Related]
16. RAGE and the pathogenesis of chronic kidney disease.
D'Agati V; Schmidt AM
Nat Rev Nephrol; 2010 Jun; 6(6):352-60. PubMed ID: 20421886
[TBL] [Abstract][Full Text] [Related]
17. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.
Tanji N; Markowitz GS; Fu C; Kislinger T; Taguchi A; Pischetsrieder M; Stern D; Schmidt AM; D'Agati VD
J Am Soc Nephrol; 2000 Sep; 11(9):1656-1666. PubMed ID: 10966490
[TBL] [Abstract][Full Text] [Related]
18. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.
Wendt T; Bucciarelli L; Qu W; Lu Y; Yan SF; Stern DM; Schmidt AM
Curr Atheroscler Rep; 2002 May; 4(3):228-37. PubMed ID: 11931721
[TBL] [Abstract][Full Text] [Related]
19. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes.
Schmidt AM; Stern DM
Trends Endocrinol Metab; 2000 Nov; 11(9):368-75. PubMed ID: 11042467
[TBL] [Abstract][Full Text] [Related]
20. Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats.
Hallam KM; Li Q; Ananthakrishnan R; Kalea A; Zou YS; Vedantham S; Schmidt AM; Yan SF; Ramasamy R
Aging Cell; 2010 Oct; 9(5):776-84. PubMed ID: 20670350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
